Medical News

EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction

8. 3. 2022 Source: Heart Failure

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had…

Fexofenadine –⁠ Non-Sedative and Immunomodulatory Antihistamine in the Treatment of Allergic Symptoms

One of the biggest limitations of traditional antihistamines is the sedative effect on the central nervous system. Newer antihistamines do not cause sedation, are not associated with serious side…

3. 3. 2022 Source: Viral infections

Does gliflozin treatment for heart failure have greater benefits in diabetics?

Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by several molecules including empagliflozin. The EMPEROR-Reduced study monitored the impact of…

3. 3. 2022 Source: Heart Failure

Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight

Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low…

3. 3. 2022 Source: Thromboprophylaxis

Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?

Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for…

3. 3. 2022 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation

A recent report from real clinical practice summarizes the experiences of physicians with dabigatran therapy and the reversal of its anticoagulant effect using idarucizumab in 10 patients before…

1. 3. 2022 Source: Anticoagulant Treatment

Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF

On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the determination of the amount and conditions of reimbursement from health insurance for a drug containing…

28. 2. 2022 Source: Venous Insufficiency

Metamizole, even after 100 years on the market, remains an important component of postoperative pain therapy

Metamizole has been used in the therapy of a wide range of acute and chronic pains for 100 years. Thanks to a number of advantages, it still represents one of the most frequently used analgesics in…

28. 2. 2022 Source: Analgesia

Administration of Erdosteine after Severe COVID-19 in the Early Period after Discharging Patients from the Healthcare Facility

Erdosteine is a mucomodulatory drug used in the treatment of various acute and chronic respiratory diseases. According to available evidence, its mechanism of action is complex, encompassing not only…

28. 2. 2022 Source: Cough Therapy

Orally Administered Berotralstat in the Prevention of Hereditary Angioedema Attacks

Berotralstat is an oral medication administered once daily, developed to prevent hereditary angioedema (HAE) attacks. It is a kallikrein protease inhibitor, which plays a key role in the pathogenesis…

25. 2. 2022 Source: Hereditary Angioedema

1 … 83 84 85 86 87 … 164

Back Filter by speciality

Remove filters